Kalbe’s current corporate description identifies it as one of the most integrated publicly listed pharmaceutical companies in Southeast Asia.2

Founding

Kalbe was established in 1966 by a group of six siblings: K.L. Tjoen, Theresia H. Setiady, Khouw Lip Swan, Khouw Lip Boen (Dr. Boenyamin Setiawan), Maria Karmila, and F. Bing Aryanto. The company began operations on a very small scale, reportedly starting from a garage.

The founders initially focused on pharmaceuticals. Over subsequent decades, Kalbe expanded through organic growth, acquisitions, new product development, and diversification into consumer health, nutrition, and distribution.3

Expansion during the 1970s–1980s

One of Kalbe’s important early expansions was into the consumer health and energy-drink market. In 1977, the company entered the energy-drink business with the launch of Extra Joss, which subsequently became one of Indonesia’s recognizable energy-drink brands.4

In 1985, Kalbe expanded its pharmaceutical and consumer-health portfolio through acquisitions including PT Bintang Toedjoe and PT Hexpharm Jaya. These businesses later became important parts of the group’s pharmaceutical and consumer-health operations.5

Becoming a public company

Kalbe continued expanding through the late 1980s and early 1990s. In 1991, PT Kalbe Farma conducted its initial public offering and became listed on the Indonesian stock exchange.6

The company subsequently developed a much broader corporate structure. Its distribution operations became associated with PT Enseval Putera Megatrading, while Kalbe continued consolidating its pharmaceutical and healthcare businesses.

Consolidation

A major corporate milestone occurred in 2005–2006, when the Kalbe Group underwent consolidation. The company used mergers and acquisitions to create a more integrated healthcare group spanning pharmaceuticals, consumer products, nutrition, and distribution.7

In 2007, Kalbe introduced a new corporate logo as part of a broader transformation. The group also increased its international ambitions, with products entering markets throughout much of Southeast Asia.8

Biotechnology and advanced healthcare

During the 2010s, Kalbe increasingly moved beyond conventional pharmaceuticals. The group invested in biotechnology, oncology, stem-cell research, laboratory services, medical devices, and biologic medicines.

Notable milestones included the development of PT Kalbio Global Medika, a biotechnology-based pharmaceutical and active pharmaceutical ingredient facility in Cikarang, and the development of oncology-related manufacturing capabilities. Kalbe also became involved in stem-cell laboratory services and biologic-drug development.9

Kalbe also partnered with South Korea’s Genexine in developing biotechnology products and, during the COVID-19 pandemic, collaborated on COVID-19 vaccine development.10

Kalbe’s operations are organized around four major business divisions.11

Prescription Pharmaceuticals

The Prescription Pharmaceuticals Division develops, manufactures, and markets medicines that require prescriptions.

Its activities include:

• Branded prescription medicines
• Generic medicines
• Specialty pharmaceuticals
• Oncology
• Biologic medicines
• Medicines associated with chronic diseases
• Biotechnology products
• Vaccine-related development
• Medical and pharmaceutical partnerships

Kalbe has increasingly emphasized higher-value pharmaceutical areas such as biologics, oncology, cell therapy, and vaccines. In FY2025, prescription-pharmaceutical sales grew 11.0% year over year, according to Kalbe’s audited results announcement.12

Kalbe also supplies unbranded generic medicines, including products supporting Indonesia’s national health-insurance program, JKN.13

Consumer Health

The Consumer Health Division is responsible for products that consumers can generally purchase without a prescription.

Its portfolio includes:

• Over-the-counter medicines
• Vitamins
• Supplements
• Herbal and natural-health products
• Energy drinks
• Ready-to-drink health products

Some of Kalbe’s better-known consumer brands include:

• Promag
• Mixagrip
• Woods
• Komix
• Extra Joss
• Fitbar

The company has also expanded into products emphasizing prevention, wellness, and healthier lifestyles.14

In FY2025, Consumer Health sales increased 11.9% year over year, supported by growth in OTC medicines and health supplements.15

Nutritionals

Nutrition is one of Kalbe’s most recognizable businesses outside traditional pharmaceuticals.

The division produces products covering areas such as:

• Infant and child nutrition
• Milk and powdered nutritional products
• Adult nutrition
• Specialized medical nutrition
• Lifestyle-oriented nutrition
• Nutritional beverages

Important brands associated with Kalbe’s nutrition business include Prenagen and Diabetasol.

Kalbe consolidated much of its nutrition business through PT Sanghiang Perkasa, which became a major component of the group’s Nutritionals Division.16

In FY2025, however, Nutritionals sales declined 1.7%, with Kalbe attributing the decline primarily to weaker purchasing power affecting the powdered-milk category. The company said it was responding by focusing on affordable and lifestyle-oriented products.17

Distribution & Logistics

Distribution is one of Kalbe’s major competitive advantages.

Pharmaceutical and healthcare products require extensive distribution infrastructure because Indonesia is an archipelago of thousands of islands. Kalbe therefore developed a large distribution and logistics network capable of delivering healthcare products throughout the country.

The company currently reports 72 distribution and logistics branches across Indonesia.18

Historically, the group’s distribution activities became closely associated with PT Enseval Putera Megatrading Tbk (EPMT).

This infrastructure allows Kalbe to operate not merely as a manufacturer but as a vertically integrated healthcare group covering much of the chain from R&D, manufacturing, marketing, distribution, and logistics to consumers and healthcare providers.

Kalbe has also expanded into healthcare-related digital infrastructure.

EMOS

EMOS is a B2B order-management platform designed to help distribution channels manage orders, inventory, and supply-chain activities.

MOSTRANS

MOSTRANS is a B2B transportation and logistics platform intended to improve the management and efficiency of healthcare-product transportation.

These businesses demonstrate Kalbe’s strategy of extending beyond physical healthcare products into digital supply-chain infrastructure.19

Kalbe’s portfolio is unusually broad for an Indonesian healthcare company.

Consumer health

Nutrition

The exact portfolio changes over time as Kalbe launches, acquires, licenses, and retires products.

Kalbe operates through a large corporate group rather than a single pharmaceutical factory.

Companies and businesses associated with the group include Bintang Toedjoe, Hexpharm Jaya Laboratories, Dankos Farma, Saka Farma Laboratories, Sanghiang Perkasa, Enseval Putera Megatrading, Kalbe Nutritionals, Kalbe Genexine Biologics, Kalbio Global Medika, and others.

Kalbe’s FY2025 financial statements report numerous controlled subsidiaries across pharmaceutical, nutrition, distribution, and other activities.20

The exact number of subsidiaries varies according to whether the source counts direct subsidiaries, indirect subsidiaries, joint ventures, and other entities. Kalbe’s current corporate materials describe more than 40 subsidiaries, while another corporate overview gives a figure of 50.21

Manufacturing is an important component of Kalbe’s strategy.

The company operates production facilities meeting Indonesian and international standards and has invested in increasingly sophisticated pharmaceutical manufacturing, including:

• Conventional pharmaceuticals
• Generic drugs
• Consumer-health products
• Nutritional products
• Oncology products
• Biologics
• Pharmaceutical raw materials
• Medical products

Kalbe’s FY2025 company update says the group had 15 production facilities and around 16,000 employees, alongside its 72-branch distribution network.22

The company has also emphasized R&D and innovation, particularly in biologics, oncology, cell therapy, and vaccines.22

Although Indonesia remains Kalbe’s core market, the company has pursued international expansion.

Its products and businesses have extended into markets in Southeast Asia and other international markets, supported by subsidiaries, joint ventures, licensing arrangements, and partnerships.

The company has particularly emphasized building regional and global capabilities rather than remaining solely an Indonesian pharmaceutical manufacturer. Its historical milestones include expansion into ASEAN markets and partnerships with international pharmaceutical and biotechnology companies.23

As of 2026, Bernadette Ruth Irawati Setiady serves as Kalbe’s President Director. She has had a long career within the Kalbe Group, including leadership of the nutrition business and previous service as Kalbe’s President Director.24

Kalbe’s current leadership reflects the company’s transition from a founder-led pharmaceutical enterprise into a professionally managed, diversified healthcare group.

Kalbe is one of Indonesia’s major listed healthcare companies.

For FY2025, Kalbe reported:

• Net sales: approximately Rp35.3 trillion
• Net profit: approximately Rp3.7 trillion
• Sales growth: 8.3%
• Net-profit growth: 13.1%

The results were announced on March 30, 2026, based on audited consolidated financial statements for the year ended December 31, 2025.25

Its financial reports and annual reports are publicly available through Kalbe’s investor-relations site.26

Kalbe is a public company listed on the Indonesia Stock Exchange (IDX) under the ticker KLBF.

It has been publicly listed since 1991.27

Because of its scale and diversified healthcare portfolio, KLBF is widely followed by Indonesian investors as a major healthcare-sector stock.

Kalbe’s corporate philosophy is traditionally expressed through its “Panca Sradha” values.

Broadly, these values emphasize principles such as:

1. Trust in God
2. Integrity
3. Innovation
4. Perseverance
5. Unity/teamwork

The philosophy is intended to provide a common cultural framework across Kalbe’s various subsidiaries and business divisions.

Kalbe’s stated corporate ambition has historically centered on becoming an Indonesian healthcare company with global-scale capabilities, rather than simply being a domestic drug manufacturer.28

Kalbe is significant because it occupies several positions within Indonesia’s healthcare ecosystem simultaneously.

A conventional pharmaceutical company might primarily manufacture medicines. Kalbe, by contrast, participates in pharmaceuticals, consumer healthcare, nutrition, medical products, distribution, logistics, and digital supply-chain services.

This integration gives the company substantial reach across both healthcare professionals and ordinary consumers.

Its distribution infrastructure is particularly important in Indonesia, where geography makes nationwide healthcare distribution challenging.

Kalbe’s recent strategy has increasingly focused on moving toward higher-value healthcare businesses while maintaining its traditional consumer brands.

Key strategic areas include:

Biologics

Development and commercialization of biologic medicines and biotechnology capabilities.

Oncology

Building a broader oncology ecosystem encompassing medicines and related healthcare services.

Cell therapy

Investment in advanced healthcare technologies and cell-based treatments.

Vaccines

Participation in vaccine development and partnerships.

Medical devices

Expansion beyond pharmaceutical products into medical-device businesses.

Consumer-brand rejuvenation

Refreshing established consumer brands to remain relevant to younger and changing consumers.

Digitalization

Building digital platforms such as EMOS and MOSTRANS around the healthcare supply chain.

Kalbe’s 2026 communications specifically identify oncology, biologics, medical devices, and consumer-brand rejuvenation as continuing strategic priorities.29

Kalbe is arguably best understood not simply as a pharmaceutical company, but as a large integrated Indonesian healthcare group.

Its evolution can be summarized as:

1966: Small pharmaceutical company
1970s–1980s: Expansion into consumer health and nutrition
1991: Public listing
1990s–2000s: Consolidation and acquisitions
2010s: Biotechnology, medical services, and international expansion
2020s: Integrated healthcare, digitalization, biologics, oncology, and advanced medicine

Today, Kalbe combines pharmaceutical manufacturing, consumer brands, nutrition, healthcare innovation, and nationwide distribution under one corporate group. Its scale—around 16,000 employees, more than 40 subsidiaries, 15 production facilities, and 72 distribution branches according to its FY2025 corporate update—makes it one of the most prominent Indonesian companies in the healthcare sector.30

1. Kalbe Portal
2. LAPORAN TAHUNAN 2022 ANNUAL REPORT
3. Kalbe Portal
4. Kalbe Farma
5. LAPORAN TAHUNAN 2023 ANNUAL REPORT
6. LAPORAN TAHUNAN 2021 ANNUAL REPORT
7. PT Kalbe Farma Tbk.
8. Kalbe Portal
9. Kalbe Portal
10. Kalbe Portal
11. LAPORAN TAHUNAN 2022 ANNUAL REPORT
12. LAPORAN TAHUNAN 2023 ANNUAL REPORT
13. Kalbe Portal
14. kalbe.co.id
15. kalbe.co.id
16. kalbe.co.id
17. kalbe.co.id
18. kalbe.co.id
19. kalbe.co.id
20. kalbe.co.id
21. kalbe.co.id
22. kalbe.co.id
23. kalbe.co.id
24. kalbe.co.id
25. kalbe.co.id
26. kalbe.co.id
27. kalbe.co.id
28. kalbe.co.id
29. kalbe.co.id
30. kalbe.co.id